BRAF V600E（VE1）在甲状腺乳头状癌中的表达及其临床意义

doi:10.16150/j.1671-2870.2018.05.013

诊断学理论与实践 ›› 2018, Vol. 17 ›› Issue (05): 552-556.doi: 10.16150/j.1671-2870.2018.05.013

BRAF V600E（VE1）在甲状腺乳头状癌中的表达及其临床意义

蔡蓉^1,2, 闵学文², 陈美蓉², 沈娅婷², 石群立¹, 周晓蝶¹

1.南京大学医学院/解放军南京总医院病理科,江苏南京 210002;
2.江苏大学附属句容人民医院病理科,江苏句容 212400

收稿日期:2018-03-06 出版日期:2018-10-25 发布日期:2018-10-25
通讯作者: 周晓蝶 E-mail: zhouxiaodieammma@163.com
基金资助:
解放军南京总医院院管课题（2017047）

Expression of BRAF V600E (VE1) in thyroid papillary carcinoma and its clinical significance

CAI Rong^1,2, MIN Xuewen², CHEN Meirong², SHEN Yating², SHI Qunli¹, ZHOU Xiaodie¹

1. Department of Pathology, Medical School of Nanjing University, Nanjing General Hospital of Nanjing Command, Jiangsu Nanjing 210002, China;
2. Department of Pathology,Jiangsu University Affiliated to the People's Hospital of Jurong, Jiangsu Jurong 212004, China

Received:2018-03-06 Online:2018-10-25 Published:2018-10-25

摘要/Abstract

摘要： 目的：分析BRAF V600E、CK19及Galectin-3抗体在甲状腺乳头状癌（papillary thyroid carcinoma, PTC）中的表达情况,并结合PTC的临床病理特征,探讨BRAF V600E抗体的诊断价值。方法：对80例PTC患者的临床病理资料进行分析,并以31例结节性甲状腺肿、13例桥本甲状腺炎患者作为对照组,观察BRAF V600E、CK19、Galectin-3 3种抗体在PTC组与对照组间的表达差异,并分析BRAF V600E抗体与PTC临床病理特征间的相关性。结果：PTC患者甲状腺被膜侵犯情况与淋巴结转移率有关（P<0.05）。80例PTC患者病理组织中的BRAF V600E、CK19及Galectin-3抗体阳性率分别为62.50%、98.75%、95.00%,联合运用CK19及Galectin-3,其诊断灵敏度达95.00%;BRAF V600抗体的诊断特异度为100%,分别与CK19、Galectin-3联合运用,可提高诊断特异度。BRAF V600E抗体表达与PTC患者的年龄、性别、肿瘤直径、甲状腺被膜侵犯与否、淋巴结转移、组织学亚型等临床病理参数间均无统计学相关性（P>0.05）。结论：联合运用BRAF V600E、CK19、Galectin-3抗体有助于PTC的病理诊断,BRAF V600E抗体可起到对BRAF V600E基因突变的初筛作用。

关键词: 甲状腺乳头状癌, BRAF V600E抗体, 基因突变

Abstract: Objective: To investigate the expressions of BRAF V600E, CK19 and galectin-3 antibodies in papillary thyroid carcinoma, and study the diagnostic value of BRAF V600E antibody when in corporating with the clinicopathological characteristics of PTC. Methods: The clinicopathological data of 80 patients with PTC were analyzed; 31 cases of nodular goiter and 13 cases with Hashimoto thyroiditis were served as controls. BRAF V600E, CK19 and galectin-3 antibodies in PTC and control group were detecteds and the correlation between BRAF V600E antibody and clinicopathological characteristics of PTC was analyzed. Results: Correlation between thyroid membrane invasion and lymph node metastasis was observed in PTC patients(P<0.05). The positive rates of BRAF V600E, CK19 and galectin-3 antibodies in patients with PTC were 62.50%, 98.75%, 95.00%, respectively. The sensitivity of CK19 combined with galectin-3antibodies was 95.00%, and the specificity of BRAF V600 antibody was 100%. The specificity of CK19 and galection-3 antibodies could be improved by combining with BRAF V600 antibody. There was no statistical correlation between expression of BRAF V600E antibody and age, gender, lesion size, thyroid membrane invasion, lymph node metastasis, histological subtype of PTC (P>0.05). Conclusions: The combined detection of BRAF V600E, CK19 and Galectin-3 antibodies is helpful for the pathological diagnosis of PTC.Meanwhile, BRAF V600E antibody plays a preliminary screening role for the mutation of BRAF V600E gene.

Key words: Papillary thyroidcarcinoma, BRAF V600E antibody, Gene mutation

中图分类号:

R736.1

蔡蓉, 闵学文, 陈美蓉, 沈娅婷, 石群立, 周晓蝶. BRAF V600E（VE1）在甲状腺乳头状癌中的表达及其临床意义[J]. 诊断学理论与实践, 2018, 17(05): 552-556.

CAI Rong, MIN Xuewen, CHEN Meirong, SHEN Yating, SHI Qunli, ZHOU Xiaodie. Expression of BRAF V600E (VE1) in thyroid papillary carcinoma and its clinical significance[J]. Journal of Diagnostics Concepts & Practice, 2018, 17(05): 552-556.

参考文献

[1] Jemal A, Bray F, Center MM, et al.Global cancer statistics[J]. CA Cancer J Clin,2011,61(2):69-90.
[2] Tuttle RM, Ball DW, Byrd D, et al.Thyroid carcinoma[J]. J Natl Compr Canc Netw,2010,8(11):1228-1274.
[3] Kim SK, Song KH, Lim SD, et al.Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis[J]. Thyroid,2009,19(2):137-141.
[4] 滕晓东, 王丽君, 姚洪田, 等. 细胞角蛋白19、galectin-3、HBME-1在甲状腺病变上的表达及鉴别诊断意义[J]. 中华病理学杂志,2004,33(3):212-216.
[5] 陈云新, 沈丹华, 孙昆昆, 等. 甲状腺微小乳头状癌中Galectin-3、CK19、HBME-1和CD56的表达及意义[J]. 临床与实验病理学杂志,2010,26(4):425-428.
[6] 佟杰, 王岩, 笪冀平. CK19HBME-1Galectin-3等表达在甲状腺乳头状微小癌与良性病变鉴别诊断中的意义[J]. 中华肿瘤杂志,2011,33(8):599-604.
[7] 郑璐滢, 朱建善, 王家东, 等. Galectin-3、CK19和TPO表达在甲状腺良恶性肿瘤病理诊断中的价值[J]. 临床与实验病理学杂志,2005,20(4):449-452.
[8] 邓敏, 叶顾萍, 马建中, 等. 甲状腺乳头状癌中CK19、Galectin-3、HBME-1和TPO的表达及意义[J]. 临床与实验病理学杂志,2011,27(8):843-846.
[9] 白杨, 孙璐, 郭爱桃, 等. CK19、galectin-3和syndecan-1在甲状腺乳头状病变鉴别诊断中的意义[J]. 诊断病理学杂志,2013,20(12):771-774.
[10] 怀建国, 蒋艳, 杨小苗, 等. 免疫组化联合检测在甲状腺乳头状病变诊断中的意义[J]. 诊断病理学杂志,2015,22(7):433-435.
[11] Kim TY, Kim WB, Rhee YS, et al.The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma[J]. Clin Endocrinol (Oxf),2006,65(3):364-368.
[12] Yip L, Nikiforova MN, Carty SE, et al.Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation[J]. Surgery,2009,146(6):1215-1223.
[13] Xing M, Alzahrani AS, Carson KA, et al.Association between BRAF V600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol,2015,33(1):42-50.
[14] Prescott JD, Sadow PM, Hodin RA, et al.BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence[J]. Surgery,2012,152(6):984-990.
[15] Abd Elmageed ZY, Sholl AB, Tsumagari K, et al.Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer[J]. Surgery,2017,161(4):1122-1128.
[16] 陈公仆, 王圣应, 郑绪才. 超声引导下细针穿刺细胞学检查对鉴别甲状腺良恶性肿瘤的价值[J]. 安徽医学,2017,38(12):1570-1571.

BRAF V600E（VE1）在甲状腺乳头状癌中的表达及其临床意义

Expression of BRAF V600E (VE1) in thyroid papillary carcinoma and its clinical significance

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王文涵, 夏蜀珺, 詹维伟. 长链非编码RNA ENST00000489676在超声评估甲状腺乳头状癌颈部淋巴结转移中的应用[J]. 诊断学理论与实践, 2022, 21(04): 514-519.
[2]	郝旭, 王伟铭. 依靠肾活检确诊的以肾脏病变为主要表现的法布里病1例报告[J]. 诊断学理论与实践, 2022, 21(04): 527-529.
[3]	徐琛莹, 李嫣然, 倪晓枫, 徐上妍, 林青. 超声预测老年甲状腺乳头状癌患者颈部淋巴结转移的效能及相关超声征象分析[J]. 诊断学理论与实践, 2022, 21(03): 343-348.
[4]	周璐, 雷航, 洪叶, 金爽, 董永勤, 王学锋, 蔡晓红. 一个新的ABOA*等位基因导致的A_wB亚型及其分子机制研究[J]. 诊断学理论与实践, 2021, 20(06): 547-551.
[5]	况李君, 陶玲玲, 詹维伟, 李伟伟, 樊金芳, 周伟. 负压细针抽吸和毛细抽吸活检法穿刺洗脱液中甲状腺球蛋白测定在甲状腺乳头状癌淋巴结转移中的诊断价值比较[J]. 诊断学理论与实践, 2021, 20(04): 367-371.
[6]	杨一娴, 倪仲馨, 夏蜀珺, 周伟, 詹维伟. 多灶性与单灶性甲状腺乳头状癌的临床病理特征及超声表现的比较[J]. 诊断学理论与实践, 2021, 20(02): 168-172.
[7]	王星, 汪蓉晖, 张桂萍, 董屹婕, 周伟, 詹维伟. 10 388个甲状腺结节行超声引导下细针抽吸活检的甲状腺癌各亚型诊断准确率的10年研究[J]. 诊断学理论与实践, 2020, 19(04): 359-363.
[8]	雷航, 范亮峰, 蔡晓红, 王钰箐, 刘曦, 金沙, 沈伟, 陆琼, 向东, 王学锋, 邹纬. 中国人群血型ABO亚型的分子基础研究[J]. 诊断学理论与实践, 2020, 19(04): 364-369.
[9]	杜月月, 杜军, 沈倩, 葛绾宇, 吴海波. Warthin瘤样甲状腺乳头状癌1例及临床病理观察[J]. 诊断学理论与实践, 2020, 19(02): 188-190.
[10]	彭真萍, 项喜喜, 张苏江, 李佳明. 以类白血病反应为首发表现的慢性中性粒细胞白血病二例并文献复习[J]. 诊断学理论与实践, 2020, 19(02): 122-128.
[11]	杨志芳, 方国平, 詹维伟, 吉日. 去分化实体型甲状腺乳头状癌伴黏膜相关淋巴组织结外边缘区淋巴瘤1例病理特征并文献分析[J]. 诊断学理论与实践, 2019, 18(05): 548-554.
[12]	余小情, 詹维伟, 周伟, 吴宇, 王怡, 李伟伟, 陶玲玲, 樊金芳. 甲状腺乳头状癌与淋巴结密度相关的临床及超声特征分析[J]. 诊断学理论与实践, 2019, 18(05): 555-559.
[13]	王登峰, 崔文燕, 邹纬, 李芳, 王学锋, 蔡晓红. α-1,3- N-乙酰半乳糖胺基转移酶p.M142I突变导致A_x亚型的分子机制研究[J]. 诊断学理论与实践, 2018, 17(03): 260-265.
[14]	陆静, 胥雨菲, 卿艳荣, 韩聪, 李牛, 郁婷婷, 姚如恩, 王剑. 一个Rett综合征合并努南综合征家系的基因诊断[J]. 诊断学理论与实践, 2018, 17(02): 147-150.
[15]	金佩佩, 梁茜, 戴菁, 丁秋兰, 孙顺昌, 王学锋. 一例2N型遗传性血管性血友病家系的表型诊断和基因型分析[J]. 诊断学理论与实践, 2018, 17(02): 151-154.